Events during the quarter
During the quarter, IRLAB received the green light from the data safety monitoring board (DSMB) of pirepemat's React-PD Ph 2b study. The board unanimously recommended the study continuation. At the end of Q3, IRLAB achieved completion of React-PD enrolment, with >100 patients recruited into the study, sufficient to demonstrate a potential treatment effect. In September, IRLAB secured additional patent protection for its two lead drug candidates mesdopetam and pirepemat, extending their patent protection in Europe/US, respectively, extending patent protection into the early 2040s. Starting from 1 August, Kristina Torfgård took over the CEO position from Gunnar Olsson, who remains a board member. After the reporting period, in October, IRLAB announced the initiation of a second Ph 1 study with IRL757 in healthy elderly adults 65 years and older. The first SAD/MAD Ph 1 study in healthy younger subjects was started in spring this year, finished the single ascending dose (SAD) part and is proceeding with the multiple ascending dose (MAD) according to the plan.
Aktuellt
SENASTE
